Gene Therapy

Ethical Implications of the Novartis Lottery

Nascent Transcript Author: Anna Miller A recent decision by the pharmaceutical company Novartis to provide 100 free gene therapy treatments for spinal muscular atrophy (SMA), a debilitating yet rare genetic condition, to patients selected through a lottery program has sparked debate about the ethical implications. SMA is a rare autosomal recessive genetic disorder caused by... Read More

ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy